Recent News:
NEW PANEL OF GLOBAL OPINION LEADERS ADVISES CORMEDIX ON TREATMENTS FOR IRON-RELATED DISEASES
04/17/2008
A new Ferroscience Advisory Board has begun providing cutting-edge expertise to CorMedix on developing treatments for iron-related diseases...
More News >>
AFERRIX TO HELP CORMEDIX DEVISE DIAGNOSTIC BIOMARKER TEST
04/17/2008
CorMedix has signed an agreement with Aferrix – a specialized diagnostic company – to help establish an inexpensive, readily available diagnostic biomarker test for urinary labile iron. This new test will support...
More News >>
CorMedix, Inc.
CorMedix, Inc. is a development-stage biopharmaceutical company based in
Summit, New Jersey. We seek to fulfill selected, significant unmet medical needs at the "cardiorenal crossroads" – the therapeutic intersection of cardiovascular disease and kidney (renal) disease. Our therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy.
Our position emphasizes treating kidney diseases and reducing the commonly associated cardiovascular and metabolic complications – in effect, "treating the kidney to treat the heart."